Background A strong association has been documented between HLA-B*15:02 and carbamazepine-induced severe cutaneous adverse reactions (SCARs) in Asians. Human leucocyte antigen testing is potentially valuable in many countries to facilitate early recognition of patient susceptibility to SCARs. Objectives To determine the cost-effectiveness of universal HLA-B*15:02 screening in preventing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in an ethnically diverse Malaysian population. Methods A hybrid model of a decision tree and Markov model was developed to evaluate three strategies for treating newly diagnosed epilepsy among adults: (i) carbamazepine initiation without HLA-B*15:02 screening (current practice); (ii) universal HLA-B*15:02 screening prior to carbamazepine initiation; and (iii) alternative treatment [sodium valproate (VPA)] prescribing without HLA-B*15:02 screening. Base-case analysis and sensitivity analyses were performed over a lifetime time horizon. Incremental cost-effectiveness ratios were calculated. Results Both universal HLA-B*15:02 screening and VPA prescribing were dominated by current practice. Compared with current practice, universal HLA-B*15:02 screening resulted in a loss of 0Á0255 quality-adjusted life years (QALYs) at an additional cost of 707 U.S. dollars (USD); VPA prescribing resulted in a loss of 0Á2622 QALYs at an additional cost of USD 4127, owing to estimated differences in antiepileptic treatment efficacy. Conclusions Universal HLA-B*15:02 screening is unlikely to be a cost-effective intervention in Malaysia. However, with the emergence of an ethnically diverse population in many other countries, this may render HLA-B*15:02 screening a viable intervention when an increasing proportion of the population is at risk and an equally effective yet safer antiepileptic drug is available.
Summary
Background A strong association has been documented between HLA-B*15:02 and carbamazepine-induced severe cutaneous adverse reactions (SCARs) in Asians. Human leucocyte antigen testing is potentially valuable in many countries to facilitate early recognition of patient susceptibility to SCARs. Objectives To determine the cost-effectiveness of universal HLA-B*15:02 screening in preventing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in an ethnically diverse Malaysian population. Methods A hybrid model of a decision tree and Markov model was developed to evaluate three strategies for treating newly diagnosed epilepsy among adults: (i) carbamazepine initiation without HLA-B*15:02 screening (current practice); (ii) universal HLA-B*15:02 screening prior to carbamazepine initiation; and (iii) alternative treatment [sodium valproate (VPA)] prescribing without HLA-B*15:02 screening. Base-case analysis and sensitivity analyses were performed over a lifetime time horizon. Incremental cost-effectiveness ratios were calculated. Results Both universal HLA-B*15:02 screening and VPA prescribing were dominated by current practice. Compared with current practice, universal HLA-B*15:02 screening resulted in a loss of 0Á0255 quality-adjusted life years (QALYs) at an additional cost of 707 U.S. dollars (USD); VPA prescribing resulted in a loss of 0Á2622 QALYs at an additional cost of USD 4127, owing to estimated differences in antiepileptic treatment efficacy. Conclusions Universal HLA-B*15:02 screening is unlikely to be a cost-effective intervention in Malaysia. However, with the emergence of an ethnically diverse population in many other countries, this may render HLA-B*15:02 screening a viable intervention when an increasing proportion of the population is at risk and an equally effective yet safer antiepileptic drug is available.
• Beyond Asia, this testing is potentially valuable owing to the increased ethnic diversity driven by modern immigration, leading to an increasing proportion of the population at risk.
What does this study add?
• This study may provide a useful cost-effectiveness template for others to use in evidence-based decision making.
• Although universal HLA-B*15:02 screening reduced the incidence of CBZ-induced SJS/TEN, it was more costly and less effective than current practice.
• Given the emergence of an ethnically diverse population in many countries, HLA-B*15:02 screening may be used when the at-risk population is increasing and an effective, safer antiepileptic drug for HLA-B*15:02 carriers is available at acceptable cost.
Severe cutaneous adverse reactions (SCARs), predominantly represented by Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), 1 are the most severe, life-threatening idiosyncratic reactions. Although rare, SCARs impose a significant public health burden because of high mortality and morbidity. [2] [3] [4] More importantly, 30-70% of surviving patients suffer from SJS/TEN sequelae that could last a lifetime. [4] [5] [6] Medication use is related to 80% of SCAR cases. 3 Among a wide spectrum of medications reported to be causal in SCARs, [7] [8] [9] carbamazepine (CBZ) is the most highly investi- With the rising trend of modern immigration worldwide leading to increased ethnic diversity in many countries, it is fundamental to incorporate this differential susceptibility to SCARs among people in an ethnically diverse population in order to better understand the cost-effectiveness of HLA testing in supporting informed decision making. Using the example of Malaysia, which is a multiethnic country, this study aimed to determine the cost-effectiveness of universal HLA-B*15:02 screening prior to CBZ initiation in an ethnically diverse population.
Materials and methods
Human research ethics approval was granted by the institutional review boards of the University of Malaya Medical Centre (UMMC) (reference number: 1135.15) and Monash University (reference number: CF15/2497 -2015001009).
Model structure
A hybrid model consisting of a decision tree and a Markov model was adapted from previous studies to project the cost and health outcomes of three treatment strategies to prevent CBZ-induced SJS/TEN. 16, 17 The model began with a decision tree emulating different treatment strategies (Fig. 1 ). All patients subsequently encountered two possible outcomes at the end of the decision tree: (i) the development of SJS/TEN; (ii) no development of SJS/TEN. A Markov model with a 1-year cycle length was developed to estimate the lifetime effects of each outcome. In those who developed SJS/TEN, they may either have recovered with/without sequelae and have been treated with an alternative antiepileptic drug (AED), or have died, whereas those who did not develop SJS/TEN continued to be treated with an AED and may have either been in remission, have uncontrolled epilepsy or have died (Fig. 2a, b) . As recommended by the Malaysian Pharmacoeconomics Guideline, 18 base-case analysis was performed using the societal perspective over a lifetime time horizon. Utilities and costs were assigned to each clinical event and health state in annual cycles, and discounted at 3% annually. The analyses were performed with Excel â (Microsoft, Redmond, WA, U.S.A.).
Target population
The and TPM (HR 0Á84; 95% CI 0Á70-1Á01), 23 respectively. The differential efficacy and safety of AEDs were reflected in our model through annual probabilities of remission and treatment failure as a result of inadequate seizure control and unacceptable adverse events, and were assumed constant after 6 years. 24 Generally, patients with epilepsy have an increased risk of mortality than the general population, [25] [26] [27] [28] [29] which is reflected by a 42% increase in mortality [standardized mortality ratio (SMR) 1Á42; 95% CI 1Á16-1Á72] for newly diagnosed patients with epilepsy and a twofold increase in mortality (SMR 2Á05; 95% CI 1Á83-2Á26) for patients with uncontrolled epilepsy. 30 It was assumed that there was no increased risk among patients who were in remission. Lifelong epilepsy treatment was assumed as there is limited evidence that supports AED withdrawal in seizure-free adults, 31 owing to the higher-than-average risk of seizure relapse associated with adult-onset epilepsy and partial seizures. 32 Predictive value of HLA-B*15:02 genotyping An ethnicity-weighted prevalence of HLA-B*15:02 carriers in Malaysia was estimated to be 15% (95% CI 13-18) based on a meta-analysis of the respective allele frequency among the three major ethnicities -Malay, Chinese and Indian (Appendix S1; see Supporting Information). [33] [34] [35] [36] The ethnicity-specific incidence of CBZ-induced SJS/TEN was assumed to be similar to Singapore, owing to historical similarities. 37 The ethnicity-weighted incidence of CBZinduced SJS/TEN for the general population in Malaysia was estimated to be 0Á46%. Using the association between HLA-B*15:02 and CBZ-induced SJS/TEN in the Malaysian population (OR 221; 95% CI 4-12 695), 11 the probabilities of CBZinduced SJS/TEN in patients with and without HLA-B*15:02 were calculated to be 2Á95% and 0Á01%, respectively (Appendix S2; see Supporting Information). We assumed that the probability of VPA-induced SJS/TEN was similar to CBZ-induced SJS/TEN in patients who were negative for HLA-B*15:02, whereas a zero probability of TPMinduced SJS/TEN was assumed, as evidence suggests that the incidence of VPA-induced SJS/TEN ranges from 0 to 0Á5 per 10 000, 7, 21 and no SJS/TEN cases have been reported for TPM. 
Costs and utilities
From a societal perspective, costs included were (i) direct medical costs (HLA-B*15:02 test, epilepsy treatment, SJS/TEN event and sequelae treatment); (ii) direct nonmedical costs (transportation and additional food expenditure); and (iii) indirect costs (productivity loss due to illness) ( Table 1 ). The costs were converted to 2015 Malaysian Ringgits (MYR) and U.S. dollars (USD) using the consumer price index and exchange rate. 38, 39 A bottom-up, microcosting was employed to determine the cost of a SJS/TEN event. Based on the resource utilization data collected from 19 patients diagnosed with SJS/TEN and hospitalized in UMMC from 1 January 2013 to 31 December 2014 (four were CBZ-induced) and institution-specific cost data, the average cost of a SJS/TEN event was MYR 7729 (USD 1876) using a nonparametric bootstrap method with 10 000 resamplings.
For the cost of epilepsy management, it was assumed that patients had three specialist visits per year, with constant drug costs throughout treatment. The annual cost of epilepsy treatment was estimated to be MYR 982 (USD 238) with CBZ, MYR 1000 (USD 243) with VPA and MYR 5581 (USD 1355) with TPM.
As severe dry-eye syndrome (DES) was the most common late ocular complication of SJS/TEN, 6,40 the annual cost of DES treatment was estimated to be MYR 554 (USD 135) ( Table 1) . Direct nonmedical costs comprised transportation costs and additional food expenditure incurred by the patient and/or a caregiver during hospital visits related to SJS/TEN, and clinic visits for epilepsy and DES. These were calculated based on government-approved rates and a national survey. 41, 42 Indirect cost was estimated based on daily productivity loss derived using age-specific mean daily wage and the number of days lost as a result of illness 43 -1 day for follow-up, and average length of hospital stay for a SJS/TEN event in this study. The utility of each health state was derived for the qualityadjusted life year (QALY) estimation based on patient interviews using the European Quality of Life-5 Dimensions (EQ-5D)-3L questionnaire or published literature. 16, 44, 45 The utility of SJS/TEN elicited from patient interviews was derived from a Malaysian EQ-5D tariff. 46 As there were no data for patients with epilepsy with DES, we estimated this utility using the multiplicative approach of Ara and Brazier. 47 
Main outcome measures
The primary outcome was the incremental cost-effectiveness ratio (ICER; incremental cost per QALY gained) for universal HLA-B*15:02 screening or VPA prescribing vs. current practice over the lifetime analytic horizon. Secondary outcome was the number of patients who would need to be screened [number needed to be screened (NNS)] to avert one SJS/TEN event. 48 was used to determine the optimal strategy in base-case and sensitivity analyses.
49,50

Sensitivity analyses
To determine the robustness of the estimates from the basecase analysis, several sensitivity analyses were performed. A series of one-way sensitivity analyses were performed to investigate the effects of altering each parameter within the plausible ranges (Table 1 ). In addition, a probabilistic sensitivity analysis (PSA) was employed to assess the simultaneous impact of parameter uncertainties using a Monte Carlo simulation with 1000 replicates of parameters sampled from the assigned distributions (Table 1) . A cost-effectiveness acceptability curve was generated to illustrate the probability of each strategy being cost-effective for a given willingness-to-pay (WTP) threshold.
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A threshold analysis was performed to determine the critical value of the probability of CBZ-induced SJS/TEN in HLA-B*15:02-positive patients that drives universal HLA-B*15:02 screening to be cost-effective at the WTP threshold of MYR 37 000 (USD 8982) per QALY.
A scenario analysis was performed to examine the robustness of cost-effectiveness findings when the Malaysia Ministry of Health (MOH) fee schedule for foreigners was used in the direct medical costs estimation in our model. 52 This was assumed to represent the actual costs of the services, including all administrative costs, professional fees and relevant costs incurred in the provision of medical services.
Results
Base-case analysis
In base-case analysis, both universal HLA-B*15:02 screening and VPA prescribing were dominated by current practice. Compared with current practice, universal HLA-B*15:02 screening resulted in a loss of 0Á0255 QALYs at an additional cost of MYR 2912 (USD 707), whereas VPA prescribing resulted in a loss of 0Á2622 QALYs at an additional cost of MYR 17 002 (USD 4127) ( Table 2) . As for seizure control, the highest number of patients with 12-month remission was estimated in current practice (n = 847), followed by universal HLA-B*15:02 screening (n = 833) and VPA prescribing (n = 740).
In the universal HLA-B*15:02 screening and VPA prescribing, there was one patient with SJS/TEN per 10 000 vs. 46 in current practice. The NNS to prevent one SJS/TEN event was 222.
Sensitivity analyses
Tornado plots illustrate the sensitivity of the incremental costs and incremental QALYs to the 10 most influential parameters in the universal HLA-B*15:02 screening and VPA prescribing vs. current practice (Figs 3, 4) . It was demonstrated that the HR of efficacy associated with VPA had the greatest potential impact on both incremental costs and incremental QALYs. Another parameter that significantly influenced the incremental costs was discount rate of cost, whereas the key driver of the incremental QALYs was the probability of CBZ-induced SJS/TEN in HLA-B*15:02-positive patients. The PSA revealed that, at the WTP threshold of MYR 37 000 (USD 8982) per QALY, current practice was cost-effective in 96% of simulations (Fig. 5 ).
Compared with current practice, the threshold analysis suggested that the ICER of universal HLA-B*15:02 screening would fall below the WTP threshold when the probability of CBZinduced SJS/TEN in HLA-B*15:02-positive patients increased from 2Á9% to 15Á4%.
When the MOH fee schedule for foreigners was used for direct medical cost estimation, the ICER findings remained unchanged, with a modest reduction in the incremental costs for both universal HLA-B*15:02 screening and VPA prescribing. Similar PSA findings were obtained where current practice was cost-effective in 93% of simulations at the WTP threshold (Appendix S3; see Supporting Information).
Discussion
This economic evaluation of treatment strategies to prevent CBZ-induced SJS/TEN in adult patients with epilepsy demonstrates that the use of either universal HLA-B*15:02 screening or VPA prescribing is likely to lead to worse clinical and economic outcomes than current practice. Although both treatment strategies reduced the incidence of CBZ-induced SJS/TEN, both strategies were more costly and less effective than current practice. This information is of use to healthcare policy-and decision-makers when deciding on the position of universal HLA-B*15:02 screening in Malaysia.
The cost-effectiveness findings were attributed to the reduced clinical efficacy of alternative AEDs, leading to poorer seizure management, resulting in overall QALY loss. Given the low positive predictive value of the HLA-B*15:02 genotyping (2Á9%), 15Á3% of patients who test positive would be switched to an alternative AED -VPA in this case -whereas only 2Á9% of them would develop SJS/TEN if treated with CBZ. As a result, the QALYs gained from averting SJS/TEN could not offset the QALY loss from suboptimal seizure control with VPA in the universal HLA-B*15:02 screening approach. For VPA prescribing, all patients were worse off, as indicated by the larger QALY loss. Despite the relative lack of cost difference between CBZ and VPA, which was unique to Malaysia, our findings are somewhat generalizable to other countries. In a situation where a larger drug cost difference exists, VPA prescribing would likely be a more unfavourable strategy owing to the higher cost incurred.
The findings of universal HLA-B*15:02 screening being dominant were robust in a series of sensitivity analyses. In the one-way sensitivity analyses, changing these variables in our model did not alter the cost-effectiveness results. Furthermore, the PSA showed that universal HLA-B*15:02 screening had only a 4% probability of being cost-effective at the MYR 37 000 (USD 8982) per QALY threshold. Although increased probability of CBZ-induced SJS/TEN in HLA-B*15:02-positive patients had a substantial impact on the incremental QALY, the overall cost-effectiveness findings remain unchanged owing to the low likelihood of a fivefold increase (from 2Á9% to 15Á4%) in the probability of CBZ-induced SJS/TEN in HLA-B*15:02-positive patients, in order for universal HLA-B*15:02 screening to be cost-effective in Malaysia. Contrary to previously published cost-effectiveness studies from Thailand and Singapore, 16, 37 our model incorporated several additional aspects to improve the validity of this analysis. Firstly, the long-term differential impacts of AEDs on seizure control and other adverse drug reactions (ADRs) were taken into account. In addition, a systematic review of economic evaluations of pharmacogenetic testing for ADR prevention highlighted the unrealistic scenario of an alternative drug having zero ADR incidence in these economic evaluations, which would lead to a bias towards pharmacogenetic testing. 53 This is in agreement with our findings, which were sensitive to both variations in seizure remission and treatment failure rates between AEDs. This implies that the assumption of similar efficacy and zero incidence of other ADRs among AEDs is potentially misleading. Secondly, a lifelong AED treatment was modelled in our study, which would be representative of real-world clinical practice based on the current evidence base. 31, 32 A few limitations of the study deserve discussion. The choice of alternative AEDs modelled was confined to VPA and TPM only. Although phenytoin may be deemed to be a better substitute, a meta-analysis confirmed a clinically relevant association between the HLA-B*15:02 allele and phenytoin-induced SJS/ TEN. 54 Therefore, VPA and TPM were selected on the basis of the low reported incidence rates of SJS/TEN used as monotherapy. 7, 21 Moreover, the paucity of evidence related to comparative efficacy among AEDs meant that newer AEDs were not included for comparison. It is also important to note that the choice of alternative AED may differ in other countries; thus, an understanding of the local alternative AED is essential for accurate modelling. In addition, the full spectrum of long-term SJS/TEN sequelae was not captured. Despite several severe complications of SJS/TEN having been documented, 55 the evidence remains scant. Thus, an accurate estimate could not be derived with the current evidence, potentially leading to an underestimation of the cost of SJS/TEN sequelae. Amniotic membrane transplant, an emerging treatment for severe ocular manifestations of SJS/TEN, 56,57 is yet to be adopted in Malaysia, and was not considered in the model. Beyond Asia, our study in an ethnically diverse population may provide a useful cost-effectiveness template for other countries owing to the rapidly changing landscape of racial and ethnic compositions worldwide. In comparison with other cost-effectiveness findings of HLA-B*15:02, it is highly suggestive that its economic value is dependent on the ethnic composition in the country and their associated susceptibility to SCAR. Notably, in the U.S.A., it is forecast that no racial or ethnic group will constitute a majority of the population within four decades; Asians are projected to be the largest immigration group by 2055. 54 Through modern immigration, a substantial proportion of the U.S. population is potentially at risk of HLA-B*15:02-related SJS/TEN, thus giving rise to the need to determine the cost-effectiveness of a universal HLA-B*15:02 screening, even in a white-dominant country. In addition, it is important to address the intrinsic equity issue when conducting economic evaluations, particularly those involving genetic testing. If an economic evaluation of genetic testing has been undertaken based on a dominant ethnicity in the country, the findings may fall short of determining the value of genetic testing for a society as a whole. By considering the variation of SCAR susceptibility among different ethnicities in an economic evaluation, its findings would have embedded the element of equity, leading to informed and equitable decision-making. Based on the best available evidence, universal HLA-B*15:02 screening is unlikely to be a clinically and economically attractive preventive strategy vs. current practice, mainly driven by the reduced efficacy of alternative AED. In addition, it is important to recognize that cost-effective information must be considered with a variety of other factors, for example ethical and social issues to inform health policy development.
From a cost-effectiveness standpoint, this study suggests that universal HLA-B*15:02 screening is unlikely to be a cost-effective intervention in Malaysia vs. current practice. This information can be used along with other factors to assist policy makers in efficiently allocating limited resources. More broadly, with the emergence of an ethnically diverse population in many countries as a result of modern immigration, this may render HLA-B*15:02 screening a possible intervention when the proportion of the population at risk is increasing and an equally effective yet safer AED for HLA-B*15:02 carriers is available at an acceptable cost.
